Summary: In 407 adults with elevated cardiovascular risk or heterozygous familial hypercholesterolaemia, fixed-dose obicetrapib plus ezetimibe lowered LDL cholesterol more than placebo and either component at day 84. The estimated placebo-adjusted difference in percentage change was -48.6 percentage points (95% CI -58.3 to -38.9); cardiovascular events were not the efficacy endpoint.
PICO Summary
| Element | Detail |
|---|---|
| Population | 407 adults at 48 US sites with established or high risk of atherosclerotic cardiovascular disease, or heterozygous familial hypercholesterolaemia. LDL cholesterol was at least 70 mg/dL despite maximally tolerated lipid-lowering therapy excluding ezetimibe, or participants had statin intolerance. Median age 68 years; 43% female. |
| Intervention | Fixed-dose obicetrapib 10 mg plus ezetimibe 10 mg orally once daily for 84 days; n=102. |
| Comparator | Obicetrapib 10 mg daily alone (n=102), ezetimibe 10 mg daily alone (n=101), or placebo (n=102), with background therapy as appropriate. |
| Outcomes | Estimated differences in percentage LDL change with the combination: -48.6 percentage points versus placebo (95% CI -58.3 to -38.9), -27.9 versus ezetimibe (-37.5 to -18.4), and -16.8 versus obicetrapib (-26.4 to -7.1). Obicetrapib alone reduced LDL by 31.9% more than placebo (95% CI 22.1 to 41.6). Adverse events occurred in 51%, 54%, 53% and 37% of combination, obicetrapib, ezetimibe and placebo groups, respectively. Serious adverse events: 3%, 6%, 7% and 4%. One death occurred in each active-treatment group and none with placebo; these small numbers do not establish causation or comparative mortality safety. |
| Study Design | TANDEM: phase 3, randomised, double-blind, four-arm, placebo-controlled trial; 1:1:1:1 allocation and 84-day efficacy assessment. Co-primary endpoints were LDL percentage-change comparisons, analysed by intention to treat. Funded by NewAmsterdam Pharma. ClinicalTrials.gov NCT06005597. |
Expert Commentary
I consider TANDEM a positive lipid-lowering trial with a clear incremental effect of combining the two agents. The four-arm design is particularly useful because it separates the combination from both individual components, rather than relying only on a placebo comparison. The size of the LDL reduction is clinically interesting, but it should not be described as an observed reduction in cardiovascular events. The main limitation is the short, surrogate-endpoint design: 84 days can establish lipid efficacy but cannot adequately resolve long-term cardiovascular benefit or uncommon harm. Adverse events were more frequent in each active group than with placebo, and the small number of serious events and deaths should be reported without either alarmist attribution or reassurance beyond the data. NewAmsterdam Pharma sponsorship warrants transparent acknowledgement. Can I use this with my patients? The findings are relevant to specialist discussions about residual LDL elevation and oral treatment options, subject to current local authorisation and prescribing guidance. They do not establish that the combination should replace therapies with established outcome evidence or that statin intolerance can be assumed without assessment. I would want cardiovascular outcome results, longer safety follow-up and pragmatic comparisons with available treatment pathways before translating the attractive lipid response into a claim of proven net clinical superiority.
References
Sarraju A, Brennan D, Hayden K, et al. Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025;405(10491):1757-1768. doi:10.1016/S0140-6736(25)00721-4. PMID: 40347969.
